Loading...
XNAS
HROW
Market cap1.60bUSD
Jul 09, Last price  
42.93USD
1D
-4.75%
1Q
19.48%
Jan 2017
1,617.20%
IPO
763.78%
Name

Harrow Health Inc

Chart & Performance

D1W1MN
XNAS:HROW chart
P/E
—
P/S
5.88
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.26%
Rev. gr., 5y
40.99%
Revenues
272m
+36.41%
000000100,00010,0001,660,0009,716,00019,942,00026,774,00041,372,00051,165,00048,871,00072,476,00088,595,000130,193,000199,614,000272,303,000
Net income
-5m
L-70.60%
-46,206-4,285,000-3,304,000-4,554,000-2,531,000-954,000-5,384,000-7,643,124-10,118,000-15,899,000-19,087,000-11,985,00014,625,000168,000-3,357,000-18,007,000-14,086,000-24,411,000-17,481,000-5,139,000
CFO
44m
P
-40,056-1,763,621-2,533,485-3,570,758-2,298,311-291,160-1,900,840-4,438,944-7,055,428-11,143,000-11,215,000-8,803,000687,000950,000-1,100,0005,082,0001,705,0003,840,000-22,202,00043,864,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Harrow Health, Inc. focuses on the creation, production, and marketing of cutting-edge pharmaceutical solutions. Its business activities are primarily organized into two distinct divisions: Pharmaceutical Compounding and Pharmaceutical Drug Development. Specifically, the Pharmaceutical Compounding segment oversees the operations of the ImprimisRx enterprise. The company was established in January 2006 by Mark L. Baum and Robert J. Kammer, and its main corporate office is located in Nashville, Tennessee.
URL
https://www.harrowinc.com/
IPO date
Feb 08, 2013
Employees
217
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT